Welcome to our dedicated page for Iradimed news (Ticker: IRMD), a resource for investors and traders seeking the latest updates and insights on Iradimed stock.
iRadimed Corporation (NASDAQ: IRMD) is focused on MRI-compatible medical devices, and its news flow reflects that specialization. The company regularly issues press releases describing its financial results, product clearances, board changes, and capital allocation decisions. Investors and observers following IRMD news can see how its non-magnetic IV infusion pump systems and MRI-compatible patient vital signs monitoring systems perform in the marketplace and how management communicates about growth and operations.
Recent news has highlighted record quarterly revenue over multiple consecutive quarters, along with updates on gross margins, domestic and international sales mix, and cash flow from operations. The company also reports on its use of non-GAAP financial measures such as non-GAAP net income, non-GAAP diluted earnings per share, and free cash flow, explaining how these metrics relate to its GAAP results. Dividend announcements, including regular quarterly cash dividends and a special cash dividend, are another recurring theme in iRadimed’s news releases.
Product and regulatory developments are also covered in detail. For example, iRadimed announced FDA 510(k) clearance for its MRidium 3870 IV Infusion Pump System, described as a next-generation MRI-compatible infusion pump with a non-magnetic ultrasonic motor, non-interfering RF emissions, and advanced safety and user interface features. News items also describe the capabilities of the 3880 MRI-compatible patient vital signs monitoring system, which operates in magnetic fields up to 30,000 gauss and is designed to travel with patients between critical care units and MRI suites.
Governance and recognition-related news includes disclosures about changes in the Board of Directors and iRadimed’s inclusion in TIME’s list of America’s Growth Leaders for 2026. Conference participation announcements and earnings call schedules provide additional context for those who want to follow company presentations and management commentary. For anyone tracking IRMD, this news feed offers a consolidated view of its financial performance, product milestones, governance updates, and other corporate developments.
IRADIMED CORPORATION (NASDAQ: IRMD) reported strong first-quarter 2022 results with revenue of $12.3 million, a significant increase from $9.2 million in Q1 2021. GAAP diluted earnings per share (EPS) reached $0.20, while non-GAAP diluted EPS was $0.22. The company announced a full-year revenue guidance increase to $52.5 million to $53.2 million and non-GAAP EPS guidance of $0.96 to $1.03. Domestic sales accounted for 81.1% of total revenue, indicating strong market demand. A special dividend of $1.00 per share was also declared.
IRADIMED CORPORATION (NASDAQ: IRMD) announced the resignation of Chris Scott, the Chief Financial and Operating Officer, effective May 27, 2022. Scott has been with the company since December 2013 and is leaving to pursue other opportunities. Matt Garner, the Controller, will take on the role of interim CFO during the transition. CEO Roger Susi expressed gratitude for Scott's contributions over the years and confidence in Garner's ability to lead the finance department. A formal search for a new CFO is underway.
IRADIMED CORPORATION (NASDAQ: IRMD) announced it will release its 2022 Q1 financial results on April 29, 2022, before the market opens. A conference call will follow at 11:00 a.m. ET to discuss the results and address questions. Interested participants can dial in or join via the company’s website. IRADIMED specializes in MRI-compatible medical devices, including the MRidium® IV infusion pump and the 3880 vital signs monitoring system, both designed to enhance safety during MRI procedures.
IRADIMED CORPORATION (NASDAQ: IRMD) has announced a special cash dividend of $1.00 per share, payable on February 24, 2022, to shareholders of record by February 17, 2022. This decision reflects the company's strong financial performance, with a cash reserve of nearly $62 million at the end of 2021. The Board aims to return excess cash to its shareholders while ensuring operational and investment needs are met.
iRadimed Corporation (NASDAQ: IRMD) reported fourth-quarter 2021 revenue of $11.9 million, a 39% increase from the previous year, with net income at $3.9 million or $0.31 per diluted share. For the full year 2021, revenue reached $41.8 million, up 32%, with net income of $9.3 million or $0.74 per diluted share. The company anticipates revenue guidance for 2022 between $51.4 million and $52.2 million and GAAP EPS of $0.82 to $0.90, reflecting continued demand for its MRI-compatible devices despite supply chain challenges.
IRADIMED CORPORATION (NASDAQ: IRMD) will release its 2021 fourth quarter financial results before market opening on February 4, 2022. A conference call is scheduled for the same day at 11:00 a.m. ET to discuss these results and address questions. Interested parties can listen by dialing 1-844-413-1781 or 1-716-247-5767, entering reservation code 2899922. The call will also be streamed live online, with a recording available on the company's website for 90 days post-call.
IRADIMED CORPORATION (NASDAQ: IRMD) reported third-quarter 2021 revenue of $10.9 million, a significant increase from $7.7 million in Q3 2020. The company achieved a GAAP diluted EPS of $0.20 and a non-GAAP diluted EPS of $0.23. For the nine months ended September 30, 2021, revenue reached $29.9 million, up from $23.2 million in the same period of 2020. The company has increased its full-year guidance, anticipating revenue of $41.4 million to $41.6 million and GAAP diluted EPS of $0.60 to $0.61.
IRADIMED CORPORATION (NASDAQ: IRMD) will release its third quarter financial results for 2021 before the market opens on October 29. The management will host a conference call at 11:00 a.m. ET that same day to discuss the results and answer questions. Interested participants can dial 1-844-413-1781 for domestic calls or 1-716-247-5767 for international calls. The call will also be available via the Internet and recorded for 90 days post-call.
IRADIMED CORPORATION (NASDAQ: IRMD) reported second-quarter 2021 revenue of $9.8 million, a significant increase from $6.8 million in Q2 2020. The net income reached $1.5 million, or $0.12 per diluted share, compared to a net loss of $(2.1) million in the same quarter last year. Non-GAAP diluted EPS was $0.14, reflecting a positive trend in earnings. Guidance for Q3 2021 anticipates revenue between $10.3 million and $10.5 million and full-year revenue expectations of $40.0 million to $40.4 million.
IRADIMED CORPORATION (NASDAQ: IRMD) will release its 2021 second quarter financial results on July 30, 2021, before market opening. Management will host a conference call at 11:00 a.m. ET to discuss these results and answer questions. Interested participants can join by calling 1-844-413-1781 domestically or 1-716-247-5767 internationally, using reservation code 7590809. The call will also be available online with a recording accessible for 90 days post-call. IRADIMED is a leader in MRI-compatible medical devices, particularly known for its MRidium IV infusion pump and 3880 monitoring system.